Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer.
Sign Up to like & getrecommendations! Published in 2021 at "British journal of cancer"
DOI: 10.1038/s41416-021-01415-9
Abstract: BACKGROUND This pooled analysis of MONALEESA trials evaluated the safety of ribociclib plus endocrine therapy (RIB + ET) with a focus on dose reductions in first-line patients. METHODS In the dose reduction analysis, data were pooled from… read more here.
Keywords: analysis; safety; dose reductions; monaleesa trials ... See more keywords